BioCentury
ARTICLE | Financial News

Former Dendreon head, analyst launch biotech hedge fund

September 4, 2013 12:39 AM UTC

Mitchell Gold, former president and CEO of immunotherapy cancer company Dendreon Corp. (NASDAQ:DNDN), and biotech analyst David Miller launched biotech hedge fund Alpine BioVentures. Miller said Alpine will start as a "modestly sized fund" in the "multiple millions," but the target size of the fund is not disclosed. The fund will primarily focus on development-stage public biotechs but may also invest in private companies primarily in cancer and Orphan diseases. ...